Risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors
Diabetic Ketoacidosis (DKA) has been reported in patients with diabetes taking SGLT-2 inhibitor drugs both in clinical trials and in real life situations, particularly amongst patients taking insulin.